The European Patent Office has granted Verona pharma an additional key patent for its chronic obstructive pulmonary disease (COPD) drug,
Schlagwörter: Patentanwalt Patentrecht Biologie Agronomie Pflanzenzüchtung Naturwissenschaft Management Wirtschaft Forschug Entwicklung Strategie Berufsfelder: OrganisationUmwelt & GeologieStrategie & PlanungNeue Produkte –
New York, March 08, 2019 (GLOBE NEWSWIRE) — Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform
12 March 2019 Source: https://www.epo.org/news-issues/news/2019/20190312.html The number of patent applications filed with the European Patent Office (EPO) grew by 4.6%
The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88 Scancell Holdings PLC (LON:SCLP) has
Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is pleased
The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034 U.S.